Drugs / Naporafenib
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05907304 | Aug 2023 → Jul 2025 overdue | — | Erasca, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04294160 | Jul 2020 → Sep 2024 | colorectal cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03333343 | Jan 2018 → Oct 2026 expected | non-small cell lung carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02974725 | Feb 2017 → Apr 2024 | melanoma, non-small cell lung carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02607813 | Jan 2016 → Feb 2022 | melanoma, non-small cell lung carcinoma, ovarian carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04417621 | Oct 2020 → Feb 2027 expected | melanoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06346067 | Apr 2024 → Apr 2028 expected | melanoma | Erasca, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2024-10-24 | Erasca, Inc. | Results Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise erasca.com ↗
Positive preliminary Phase 1b SEACRAFT-1 data for naporafenib plus trametinib reinforce therapeutic potential in NRASm melanoma and further support ongoing Phase 3 SEACRAFT-2 trial |
| 2024-05-08 | Erasca, Inc. | Results Erasca Reports First Quarter 2024 Business Updates and Financial Results erasca.com ↗
We started 2024 strong with compelling survival data from a pooled analysis of mature data for naporafenib plus trametinib in patients with NRAS-mutant (NRASm) melanoma, which showed a near doubling of median overall survival (mOS) versus comparable historical controls, |
| 2023-12-11 | Erasca, Inc. | Regulatory Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma erasca.com ↗ |
| 2023-04-25 | Erasca, Inc. | Results Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma erasca.com ↗
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the publication of results in the Journal of Clinical Oncology from the expansion arm of a Phase 1b open label study evaluating pan-RAF inhibitor naporafenib plus MEK inhibitor trametinib (MEKINIST®) in patients with NRAS-mutant (NRASm) melanoma. |
All press releases naming this drug 10 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | naporafenib | “Patients and methods: In this phase Ib escalation/expansion study (ClinicalTrials.gov identifier: NCT02974725), the safety, tolerability, and preliminary antitumor activity of...” PMID 36947734 ↗ Mar 2023 |
| Known as | ERAS-254 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4583691 ↗ |
| Known as | LXH254 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02974725 ↗ |
| Known as | PAN-RAF INHIBITOR LXH254 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4583691 ↗ |
| Action | Inhibit | “pan-RAF inhibitor” NCT02607813 ↗ |
| Modality | Small molecule | — CHEMBL4583691 ↗ |
| Route | Oral | “A Phase I Dose Finding Study of Oral LXH254 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations” NCT02607813 ↗ |
| Target | BRAF | “a BRAF/CRAF protein kinases inhibitor” PMID 36947734 ↗ Mar 2023 |